Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of BST104 (Lonicera Flos Extract) in Mild to Moderate Functional Dyspepsia Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persons who was diagnosed with functional indigestion in adult over 19 years of age and did not require early medication was conducted with the participation~Exclusion Criteria:~* Persons who is allergic to natural substances and substances~* Persons who need treatment for reflux esophagitis, gastric ulcer, and acute gastritis according to gastroscopy findings~* Persons with past history of stomach or esophagus surgery, or patients who are unable to take esophagogastroduodenoscopy~* Persons who continue to apply medications that can cause ulcers such as steroids, nonsteroidal anti-inflammatory drugs and aspirin (Patients taking low-dose aspirin for prevention of cardiovascular disease were allowed)~* Persons diagnosed with malignant tumors within five years~* Persons who drink more than four times a week~* Severe liver failure (more than 2 .5 times the normal upper limit of ALT, AST, γGT)~* In case of a severe renal failure, including chronic or acute kidney failure~* Persons with uncontrolled diabetes, cerebrovascular disease,~* Persons diagnosed with diseases requiring surgery within three months~* Zollinger Ellison sy n drome, esophageal stenosis, duodenal ulcer, pancreatitis, absorption disorder, or malignant disease in the gastrointestinal tract~* Pregnant women, nursing mothers, having plans for pregnancy~* In case of participating another human study within four weeks

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Treatment group (Type: ACTIVE_COMPARATOR): The randomly assigned target was given a Lonicera Flos extract (BST104) 175 mg/day for eight weeks.
- Placebo group (Type: PLACEBO_COMPARATOR): The randomly assigned target was given a placebo for eight weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).